Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research
Zacks Research cut shares of Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday...
MarketBeat·13d ago
More News
New Strong Sell Stocks for January 20th
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Zacks·14d ago
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages
Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports...
MarketBeat·1mo ago
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position
Acorn Capital Advisors LLC boosted its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 19.9% in the second quarter, according to the company in its most recent Form 13F filing...
MarketBeat·2mo ago
Brookline Capital Management Weighs in on CADL Q4 Earnings
Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Stock analysts at Brookline Capital Management issued their Q4 2025 earnings estimates for Candel Therapeutics in a report issued on Sunday...
MarketBeat·2mo ago
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL)
Stephens reaffirmed an "overweight" rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday...
MarketBeat·2mo ago
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat...
MarketBeat·2mo ago
Nasdaq, S&P 500 Futures Set For Firm Open Ahead Of PCE Inflation Data: Why NFLX, SMX, SOFI, IOT Are On Traders' Radar
Retail sentiment, however, remains cautious, with SPY and QQQ flashing bearish on Stocktwits.
Stocktwits·2mo ago
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $24.00
Citigroup reduced their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday...
MarketBeat·3mo ago
Candel Therapeutics (NASDAQ:CADL) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...